Form 4 for PRCT PROCEPT BioRobotics Corp
Accepted 2024-11-07 00:00:00 ET · period of report 2024-11-05 · accession 0001628280-24-046469 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-11-07 | 2024-11-05+ | PRCT | Desai Antal Rohit | Dir | S - Sale | $96.33 | -100.0K | 164.4K | -38% | -$9.63M |
| MI | 2024-11-07 | 2024-11-05 | PRCT | Desai Antal Rohit | Dir | J - Other | $0.00 | -895.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-05 | S | D | 7,566 | $95.38 | 256,797 | I By The 2:22 DNA Trust | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.64 to $95.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. (F4) Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. (F8) Includes shares previously held indirectly through Mallard Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. (F9) Includes shares previously held indirectly through Kestrel Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. (F10) Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-11-05 | J | D | 62,944 | $0.00 | 0 | I Kestrel Fund, L.P. | — | — | (F4) Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. (F5) On November 5, 2024, Kestrel Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 3,316 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. (F2) CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. |
| 3 | Common | Common Stock | 2024-11-05 | S | D | 11,756 | $96.49 | 245,041 | I By The 2:22 DNA Trust | — | — | (F11) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.91 to $96.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 4 | Common | Common Stock | 2024-11-05 | S | D | 11,487 | $97.17 | 233,554 | I By The 2:22 DNA Trust | — | — | (F12) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.91 to $97.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 5 | Common | Common Stock | 2024-11-05 | S | D | 2,191 | $98.43 | 231,363 | I By The 2:22 DNA Trust | — | — | (F13) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.94 to $98.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 6 | Common | Common Stock | 2024-11-06 | S | D | 9,403 | $95.68 | 221,960 | I By The 2:22 DNA Trust | — | — | (F14) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 7 | Common | Common Stock | 2024-11-06 | S | D | 2,678 | $96.57 | 219,282 | I By The 2:22 DNA Trust | — | — | (F15) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $97.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 8 | Common | Common Stock | 2024-11-06 | S | D | 17,150 | $97.59 | 202,132 | I By The 2:22 DNA Trust | — | — | (F16) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.07 to $98.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 9 | Common | Common Stock | 2024-11-06 | S | D | 3,769 | $98.29 | 198,363 | I By The 2:22 DNA Trust | — | — | (F17) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.09 to $98.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 10 | Common | Common Stock | 2024-11-07 | S | D | 6,992 | $94.42 | 191,371 | I By The 2:22 DNA Trust | — | — | (F18) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 11 | Common | Common Stock | 2024-11-07 | S | D | 16,272 | $95.33 | 175,099 | I By The 2:22 DNA Trust | — | — | (F19) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.78 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 12 | Common | Common Stock | 2024-11-07 | S | D | 10,236 | $96.03 | 164,863 | I By The 2:22 DNA Trust | — | — | (F20) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| 13 | Common | Common Stock | 2024-11-07 | S | D | 500 | $97.54 | 164,363 | I By The 2:22 DNA Trust | — | — | |
| 14 | Common | Common Stock | 2024-11-05 | J | D | 660,302 | $0.00 | 0 | I By White Tailed Ptarmigan, LP | — | — | (F1) On November 5, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 51,245 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. (F2) CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. |
| 15 | Common | Common Stock | 2024-11-05 | J | D | 172,016 | $0.00 | 0 | I Mallard Fund, L.P | — | — | (F4) Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. (F3) On November 5, 2024, Mallard Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 8,511 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. (F2) CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. |